Phencyclidine (PCP): A Dangerous Drug, but Useful in Schizophrenia Research

@article{Murray2002PhencyclidineA,
  title={Phencyclidine (PCP): A Dangerous Drug, but Useful in Schizophrenia Research},
  author={J. B. Murray},
  journal={The Journal of Psychology},
  year={2002},
  volume={136},
  pages={319 - 327}
}
  • J. B. Murray
  • Published 2002
  • Psychology, Medicine
  • The Journal of Psychology
Abstract Phencyclidine (PCP) is a dangerous drug, and the federal government has placed it on Schedule II of the Controlled Substance Act (see http://www.mninter.net/∼publish/csa2.htm#Schedule%20III). Typically, users smoke PCP, and it is often mixed with parsley, marijuana, or cocaine. Most researchers have conducted experiments on animals rather than on people, and a few have been done on persons diagnosed with schizophrenia, so answers to questions about its addictive potential or… Expand
Evaluation of NMDA receptor models of schizophrenia: Divergences in the behavioral effects of sub-chronic PCP and MK-801
TLDR
Withdrawal from sub-chronic PCP caused a delay-dependent impairment of working memory, reduced social interaction and enhanced d-amphetamine-induced motor activity, suggesting that pharmacological antagonism at NMDA receptors is not sufficient to explain the full spectrum of PCP psychotomimetic properties. Expand
Synthesis and characterization of phencyclidine and his derivatives
Phencyclidine (PCP) or 1-phenyl-cyclohexylpiperidine is the best-known representative drug from the compound class of arylcyclohexylamines. On a pharmacological activities basis, it belongs to theExpand
The antidepressant phenelzine enhances memory in the double Y-maze and increases GABA levels in the hippocampus and frontal cortex of rats
TLDR
It was concluded that PLZ does not specifically augment memory in SI or subchronic MK-801-treated rats, and treatment with phenelzine (PLZ), a monoamine oxidase (MAO)-inhibiting antidepressant that also produces a rapid increase in brain levels of GABA, will improve memory. Expand
Effects of acute phencyclidine administration on arginine metabolism in the hippocampus and prefrontal cortex in rats
TLDR
It is demonstrated, for the first time, that a single acute administration of PCP affects animals' behaviour and arginine metabolism in the brain. Expand
Effects of withdrawal from repeated phencyclidine administration on behavioural function and brain arginine metabolism in rats
TLDR
These findings demonstrate, for the first time, the influence of the withdrawal duration on animals' behaviour and brain arginine metabolism and suggest both the residual and long‐term effects of withdrawal from repeated PCP treatment on behavioural function and brain Archerine metabolism. Expand
Antipsychotic drugs prevent the motor hyperactivity induced by psychotomimetic MK-801 in zebrafish (Danio rerio)
TLDR
The value of the zebrafish, a simple to use animal model, is demonstrated in developing some behavioral features observed in schizophrenia, which may indicate a new approach for drug screening. Expand
Antipsychotic drugs dose-dependently suppress the spontaneous hyperactivity of the chakragati mouse
TLDR
The data suggest that the spontaneous circling and hyperactivity of the ckr mouse may allow screening of candidate antipsychotic compounds, distinguishing compounds with aripriprazole-like profiles. Expand
Phencyclidine-Based New Psychoactive Substances.
TLDR
The aim of this chapter is to present a brief introductory overview of substances that have materialized as PCP-derived new psychoactive substances (NPS) in recent years and their known pharmacology. Expand
Do Acetylcholinesterase Inhibitors Have a Role in Improving Cognitive Impairment in Patients with Schizophrenia?
TLDR
Acetylcholinesterase inhibitors (AChEIs) that have been proven to be effective on psychiatric symptoms, behavioural abnormalities and cognitive dysfunction of patients with dementia may beeffective on cognitive deficit in patients with schizophrenia, and may also improve their psychopathology and behaviour. Expand
Chronic phencyclidine administration reduces the expression and editing of specific glutamate receptors in rat prefrontal cortex
TLDR
It can be inferred that the PCP treatment induced a specific and site-selective reduction of glutamatergic neurotransmission in the prefrontal cortex but not in the hippocampus, suggesting the formation of glutamate receptor subunits with slower resensitization kinetics and an increase in the Q/R editing level might generate receptor channels with a lower permeability to cations. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 52 REFERENCES
Recent advances in the phencyclidine model of schizophrenia.
TLDR
It was found that PCP-induced psychotomimetic effects are associated with submicromolar serum concentrations of PCP and the findings suggest that endogenous dysfunction of NMDA receptor-mediated neurotransmission might contribute to the pathogenesis of schizophrenia. Expand
Subanesthetic Doses of Ketamine Stimulate Psychosis in Schizophrenia
TLDR
Ketamine-induced psychotic symptoms were strikingly reminiscent of the subject's symptoms during active episodes of their illness, and antagonism of NMDA-sensitive glutamatergic transmission in brain exacerbates symptoms of schizophrenia. Expand
Phencyclidine Increases Forebrain Monoamine Metabolism in Rats and Monkeys: Modulation by the Isomers of HA966
TLDR
Data demonstrate that in the primate, PCP has potent effects on dopamine transmission in the frontal cortex, a brain region thought to be dysfunctional in schizophrenia. Expand
The role of serotonin in schizophrenia.
TLDR
5HT dysfunction might be related to Type II, or negative syndrome, schizophrenia, and the nature of this dysfunction might involve 5HT postsynaptic receptor hypersensitivity, and it is suggested that the pharmacotherapy of schizophrenia should include a 5HT- blocking component, as well as a dopamine-blocking component. Expand
Clinical implications of behavioral pharmacology research on phencyclidine.
This discussion has highlighted only some of the areas of behavioral pharmacology research with PCP, focusing largely on studies in our laboratories. Some of the areas touched upon lightly have beenExpand
Clinical implications of behavioral pharmacology research on phencyclidine.
This discussion has highlighted only some of the areas of behavioral pharmacology research with PCP, focusing largely on studies in our laboratories. Some of the areas touched upon lightly have beenExpand
Corticolimbic Dopamine Neurotransmission Is Temporally Dissociated from the Cognitive and Locomotor Effects of Phencyclidine
TLDR
It is indicated that activation of dopamine neurotransmission is not sufficient to sustain PCP-induced locomotion and impairment of working memory, and effects of PCP, including a glutamatergic hyperstimulation, may be necessary to account for the psychotomimetic and cognitive-impairing effects of this drug. Expand
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
TLDR
These data indicate that N-methyl-D-aspartate antagonists produce a broad range of symptoms, behaviors, and cognitive deficits that resemble aspects of endogenous psychoses, particularly schizophrenia and dissociative states. Expand
Abnormal excitatory neurotransmitter metabolism in schizophrenic brains.
TLDR
The hypothesis that schizophrenia results from a hypofunction of certain glutamatergic neuronal systems is supported and the therapeutic efficacy of neuroleptics may be related to increased glutamatorgic activity. Expand
Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats.
TLDR
Group II metabotropic glutamate receptors were targeted to normalize glutamatergic disruptions associated with an animal model of schizophrenia, the phencyclidine model, and an agonist of this group of receptors attenuated the disruptive effects of Phencyclidine on working memory, stereotypy, locomotion, and cortical glutamate efflux. Expand
...
1
2
3
4
5
...